AGL:LSE-ANGLE plc (GBX)

COMMON STOCK | Diagnostics & Research | LSE

Last Closing Price

GBX 55.50

Change

0.00 (0.00)%

Market Cap

GBX 0.10B

Volume

0.25M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests rare circulating tumor cells in cancer patient blood; and Ziplex multiplex analysis system that is used with the ovarian cancer clinical application and others. The company was founded in 2004 and is based in Guildford, the United Kingdom.

Company Website : http://www.angleplc.com

Address : The Surrey Research Park, Guildford, United Kingdom, GU2 7AF

Fiscal Year End : April

Currency: GBX

Country : UK

Technical Indicators

Beta : 1.22

52 Week High : 85.00

52 Week Low : 42.00

200 Day Moving Average : 62.47

50 Day Moving Average : 62.34

Shares Held By Insiders : 161.51%

Shares Held by Institutions : 29.4%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-08 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
RENX:LSE Renalytix AI plc

+10.00 (+1.79%)

 GBX0.31B N/A N/A
EKF:LSE EKF Diagnostics Holdings plc

-0.60 (-1.30%)

 GBX0.21B 56.50 19.47
NCYT:LSE Novacyt S.A

-0.50 (-0.18%)

 GBX0.21B N/A 670.96
HZD:LSE Horizon Discovery Group plc

N/A

 GBX0.16B N/A N/A
MXCT:LSE MaxCyte, Inc

+3.50 (+1.75%)

 GBX0.16B N/A N/A
GDR:LSE genedrive plc

-4.00 (-3.76%)

 GBX0.05B N/A N/A
PRM:LSE Proteome Sciences plc

-0.10 (-2.39%)

 GBX0.01B 83.80 57.77

ETFs Containing AGL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.48% 25% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.48% 25% F 46% F
Trailing 12 Months  
Capital Gain -11.90% 25% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.90% 25% F 38% F
Trailing 5 Years  
Capital Gain -34.80% 80% B- 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -34.80% 80% B- 24% F
Average Annual (5 Year Horizon)  
Capital Gain 1.89% 50% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.89% 50% F 23% F
Risk Return Profile  
Volatility (Standard Deviation) 30.15% 75% C 26% F
Risk Adjusted Return 6.28% 50% F 24% F
Market Capitalization 0.10B 38% F 47% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.25 67% D+ 19% F
Price / Cash Flow Ratio -9.38 67% D+ 83% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -36.45% 50% F 13% F
Return on Invested Capital 22.99% 100% A+ 92% A-
Return on Assets -24.24% 50% F 8% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.22 14% F 19% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector